IDH2 and acute myeloid leukemia: The IDH-mutated AML patients showed an overall survival rate of 57% at two years following standard chemotherapy treatment; decreased serum 2-HG levels in these patients on day 14 of treatment were associated with improvements in overall survival and event-free survival [131].